Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • FontMasterFlex@lemmy.world
    link
    fedilink
    arrow-up
    3
    arrow-down
    2
    ·
    1 year ago

    dude’s not saying it doesn’t work. he’s saying it doesn’t work as well as advertised. that perhaps doesn’t mean it’s only 50% effective for 100% people. perhaps it’s 100% effective for 20% of people. Think dude.

    • Jax@sh.itjust.works
      link
      fedilink
      arrow-up
      3
      arrow-down
      1
      ·
      edit-2
      1 year ago

      Yeah I’m gonna go ahead and say the guy throwing out accusations like false advertising is the one that needs to think a little more.

      Paxlovid has only ever been advertised as something that “can reduce the risk of hospitalization and death by around 89%”.

      The idea that, somehow, all of the people associated with coming to the “89%” number are somehow magically also associated with a subset of the population that responds well to it is fucking nonsense. It’s the exact same garbage logic that conspiracy theorists use.